Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
000919 Jinling Pharmaceutical
- 7.10
- +0.20+2.90%
Market Closed Dec 20 15:00 CST
4.43BMarket Cap60.17P/E (TTM)
7.25High6.88Low290.81KlotVolume6.89Open6.90Pre Close206.11MTurnover4.93%Turnover Ratio44.38P/E (Static)623.71MShares8.1452wk High1.17P/B4.19BFloat Cap5.2852wk Low7.59Limit Up590.36MShs Float29.05Historical High6.21Limit Down5.36%Amplitude0.09Historical Low0.10Dividend TTM7.09Avg Price139.26KlotAsk1.41%Div YieldTTM100Lot Size139.60KlotBid
Jinling Pharmaceutical News
Jinling Pharmaceutical (000919.SZ): Magnesium sulfate injection has been approved for registration.
On December 11, 2023, Gelonghui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a "Pharmaceutical Registration Certificate" for magnesium sulfate injection issued by the National Medical Products Administration (Notification Number: 2024S30151). Magnesium sulfate injection can be used as an anticonvulsant for pregnancy-induced hypertension, to lower blood pressure, and to treat preeclampsia and eclampsia. Magnesium sulfate plays an important role in the prevention and treatment of eclampsia, hypertensive crises, asthma, and other diseases. Currently, China's "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy (2020)" ...
Jinling Pharmaceutical Completes Cancellation of Subsidiary
Jinling Pharmaceutical: Report for the third quarter of 2024
Jinling Pharmaceutical (000919.SZ): Intends to acquire a portion of shares of Xingong Fund and equity of non-cash distribution of Xingong Fund.
GeLongHui October 21st 丨 Jinling Pharmaceutical (000919.SZ) announced that, to build the company's global strategy of "medical and health care dual platform", improve the company's medical regional market layout, and at the same time resolve the same industry competition between Nanjing New Work Investment Group Co., Ltd. (referred to as "New Work Group") controlling Nanjing Meishan Hospital Co., Ltd. (referred to as "Nanjing Meishan Hospital") and the company, the company plans to acquire 164.7317 million yuan held by New Work Group South New Work Medical Industry Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "Fund" or "New Work Fund") 28.46% of the contribution.
Unpleasant Surprises Could Be In Store For Jinling Pharmaceutical Company Limited's (SZSE:000919) Shares
The One-year Earnings Decline Is Not Helping Jinling Pharmaceutical's (SZSE:000919 Share Price, as Stock Falls Another 9.0% in Past Week
Jinling Pharmaceutical: 2024 Semi-Annual Report Summary
Jinling Pharmaceutical: Semi-Annual Report 2024
Jinling Pharmaceutical (000919.SZ) released its performance for the first half of the year, with a net income of 51.8188 million yuan, a decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
Jinling Pharmaceutical (000919.SZ): The net income in the first half of the year was 51.8188 million yuan, a year-on-year decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) announced its semi-annual report for 2024, with revenue of 1.511 billion yuan, a year-on-year increase of 4.83%; net income attributable to shareholders of listed company was 51.8188 million yuan, a year-on-year decrease of 33.16%; net income attributable to shareholders of listed company after deducting non-recurring gains and losses was 45.2629 million yuan, a year-on-year decrease of 36.04%; basic earnings per share was 0.0913 yuan.
Jinling Pharmaceutical (000919.SZ): As of July 31st, the total number of shareholders in the company is 36,202.
Jinling Pharmaceutical (000919.SZ) stated on its investor interaction platform on August 1st that as of July 31st, 2024, the total number of shareholders in the company is 36,202.
Jinling Pharmaceutical (000919.SZ): As of July 19, the total number of shareholders of the company is 36,049.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform on July 25 that as of July 19, 2024, the total number of shareholders in the company was 36,049.
Jinling Pharmaceutical (000919.SZ): As of July 10, the total number of shareholders in the company is 36,316.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform of their website today, July 15th, that as of July 10th, 2024, the total number of shareholders in the company was 36,316.
Jinling Pharmaceutical (000919.SZ): Compound sulfamethoxazole injection passed the generic drug consistency evaluation.
On July 8th, Gelonhui reported that Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory (hereinafter referred to as "Jinling Pharmaceutical Factory"), received the "Drug Supplement Application Approval Notification" (Notification No.: 2024B03021) issued and approved by the National Medical Products Administration (hereinafter referred to as "NMPA"), approving the approval of compound sulfamethoxazole injection through generic drug quality and efficacy consistency evaluation (hereinafter referred to as "generic drug consistency evaluation"). The indications for the company's compound sulfamethoxazole injection are: 1. For the treatment of adults and...
Jinling Pharmaceutical (000919.SZ): Its subsidiary, Ipratropium Bromide, has obtained a notice of approval for the marketing application of chemical raw materials.
On June 28, Gelunhui reported that Jinling Pharmaceutical (000919.SZ) recently announced that its subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as 'Dongsheng Pharmaceutical'), controlled by Jinling Pharmaceutical Co., Ltd., received the 'Chemical Active Pharmaceutical Ingredient Market Approval Notice' (Notice No. 2024YS00595) issued by the State Drug Administration for its ingredient of ipratropium bromide. Ipratropium bromide is used to relieve bronchospasm and asthma symptoms caused by chronic obstructive pulmonary disease (COPD), and is suitable for the prevention and treatment of asthma, especially for those who cannot tolerate such drugs due to the side effects of beta receptor agonists, such as muscle tremors and tachycardia.
Jinling Pharmaceutical (000919.SZ): As of June 20, 2024, the total number of shareholders of the company is 36,441.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform on June 26 that as of June 20, 2024, there were 36,441 shareholders in the company.
Jinling Pharmaceutical (000919.SZ) 2023 equity distribution: 1 yuan for every 10 shares
Jinling Pharmaceutical (000919.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Jinling Pharmaceutical (000919.SZ): As of May 10, 2024, the total number of shareholders of the company was 37,991
Gelonghui May 14 | Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that as of May 10, 2024, the total number of shareholders of the company was 37,991.
Jinling Pharmaceutical (000919.SZ): Currently, major products have not entered national collection
Gelonghui May 9丨Jinling Pharmaceutical (000919.SZ) held a performance briefing on May 9, 2024 to “ask which varieties of the company may enter collection in the future?” The company replied that at present, the company's main products have not been collected by the country. The company will pay close attention to national collection policy trends and proactively respond to possible policy changes.
Why Jinling Pharmaceutical's (SZSE:000919) Shaky Earnings Are Just The Beginning Of Its Problems
